<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04989660</url>
  </required_header>
  <id_info>
    <org_study_id>R-1154-21</org_study_id>
    <nct_id>NCT04989660</nct_id>
  </id_info>
  <brief_title>Phenol Neurolysis of Genicular Nerves for Osteoarthritic Knee Pain</brief_title>
  <official_title>Phenol Neurolysis of Genicular Nerves for Osteoarthritic Knee Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kessler Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kessler Foundation</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      As the aging and obese populations continue to increase, there is a rapidly growing number of&#xD;
      people at risk for knee osteoarthritis. Treatment typically starts conservatively with&#xD;
      analgesics, physical therapy, and bracing. Intra-articular injections with corticosteroids&#xD;
      and/or viscosupplementation may also be utilized in those with persistent knee pain.&#xD;
      Genicular nerve radiofrequency ablation (GNRFA) is an increasingly employed procedure for&#xD;
      refractory osteoarthritic knee pain with promising efficacy for pain relief. However, due to&#xD;
      its reliance on expensive equipment, additional staff, and need for specialized rooms (eg.&#xD;
      fluoroscopy suite), GNRFA is a costly procedure with limited availability. Chemical&#xD;
      neurolysis is an alternative method of nerve ablation using alcohol or phenol utilized in the&#xD;
      management of pain. Recent literature has demonstrated good efficacy for pain relief and&#xD;
      function with chemical ablation of the genicular nerves using both alcohol and phenol.&#xD;
&#xD;
      This study is a double-blind, randomized, placebo-controlled pilot study to assess the&#xD;
      efficacy of phenol neurolysis of the genicular nerves for pain and function due to refractory&#xD;
      osteoarthritic knee pain. We hypothesize that a significant improvement in both pain and&#xD;
      function will be observed with chemical neurolysis of the genicular nerves using 6% phenol&#xD;
      compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in NRS pain score from baseline</measure>
    <time_frame>Baseline, 1 month, 3 months, 6 months</time_frame>
    <description>Participants' pain will be measured using the numeric rating scale (0-10) prior to the intervention and at 1 month, 3 months, and 6 months after the intervention. Numeric rating scale ranges from 0 (no pain) to 10 (worst pain).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in WOMAC score from baseline</measure>
    <time_frame>Baseline, 1 month, 3 months, 6 months</time_frame>
    <description>Participants' function as measured by WOMAC will be measured prior to the intervention and at 1 month, 3 months, and 6 months after the intervention. WOMAC score ranges from 0 (best) to 100 (worst).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <condition>Knee Pain Chronic</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6% aqueous phenol, 1.5 mL per target site</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Isotonic saline, 1.5 mL per target site</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6% aqueous phenol</intervention_name>
    <description>1.5 mL of 6% aqueous phenol will be injected at each target genicular nerve under ultrasound guidance.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Phenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic saline</intervention_name>
    <description>1.5 mL of isotonic saline will be injected at each target genicular nerve under ultrasound guidance.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Radiographic knee osteoarthritis (Kellgren-Lawrence grade 2-4)&#xD;
&#xD;
          -  Knee pain of moderate intensity or greater (NRS of 4 or greater)&#xD;
&#xD;
          -  Knee pain for 3 months or longer&#xD;
&#xD;
          -  Persistent knee pain despite conservative treatment including oral/topical analgesics,&#xD;
             physiotherapy, intra-articular injection with corticosteroid and/or hyaluronic acid&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior total or partial knee arthroplasty in the knee(s) to be treated&#xD;
&#xD;
          -  Prior radiofrequency ablation treatment in the affected knee&#xD;
&#xD;
          -  Other rheumatological or connective tissue disease(s) affecting the knee to be treated&#xD;
&#xD;
          -  History of bleeding disorder&#xD;
&#xD;
          -  Any psychiatric or neurologic disease (eg. dementia, brain injury, etc.) that may&#xD;
             preclude reliable reporting of symptoms and response to treatment&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Recent treatment with intraarticular hyaluronic acid, platelet-rich plasma, or&#xD;
             corticosteroid injections to the affected knee in the past 3 months&#xD;
&#xD;
          -  Skin or joint infection in the knee(s) to be treated&#xD;
&#xD;
          -  Concomitant radicular pain&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul So, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kessler Institute for Rehabilitation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul So, MD</last_name>
    <phone>973-972-3606</phone>
    <email>ibaool@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kessler Institute for Rehabilitation</name>
      <address>
        <city>West Orange</city>
        <state>New Jersey</state>
        <zip>07052</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul So, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

